Trial · NCT00790933
Adverse events446
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 446
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Vedolizumab 300 mg | 594 | 2,243 | |
| other | Upper respiratory tract infection | Infections and infestations | Vedolizumab 300 mg | 379 | 2,243 | |
| other | Sinusitis | Infections and infestations | Vedolizumab 300 mg | 235 | 2,243 | |
| other | Bronchitis | Infections and infestations | Vedolizumab 300 mg | 216 | 2,243 | |
| other | Gastroenteritis | Infections and infestations | Vedolizumab 300 mg | 216 | 2,243 | |
| other | Influenza | Infections and infestations | Vedolizumab 300 mg | 208 | 2,243 | |
| other | Urinary tract infection | Infections and infestations | Vedolizumab 300 mg | 175 | 2,243 | |
| other | Abdominal pain | Gastrointestinal disorders | Vedolizumab 300 mg | 393 | 2,243 | |
| other | Crohn's disease | Gastrointestinal disorders | Vedolizumab 300 mg | 333 | 2,243 | |
| other | Nausea | Gastrointestinal disorders | Vedolizumab 300 mg | 333 | 2,243 | |
| other | Diarrhoea | Gastrointestinal disorders | Vedolizumab 300 mg | 284 | 2,243 | |
| other | Colitis ulcerative | Gastrointestinal disorders | Vedolizumab 300 mg | 251 | 2,243 | |
| other | Vomiting | Gastrointestinal disorders | Vedolizumab 300 mg | 227 | 2,243 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Vedolizumab 300 mg | 139 | 2,243 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Vedolizumab 300 mg | 482 | 2,243 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Vedolizumab 300 mg | 239 | 2,243 | |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | Vedolizumab 300 mg | 125 | 2,243 | |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Vedolizumab 300 mg | 121 | 2,243 | |
| other | Headache | Nervous system disorders | Vedolizumab 300 mg | 452 | 2,243 | |
| other | Dizziness | Nervous system disorders | Vedolizumab 300 mg | 162 | 2,243 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00790933/events